Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma, Non-Hodgkin 4Lymphoma 3Hodgkin Disease 3Recurrence 2Lymphoma, Mantle-Cell 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma, Follicular 2Burkitt Lymphoma 2Uveal Melanoma 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Plasmablastic Lymphoma 1Pediatric Brain Tumor 1Oligodendroglioma 1Neoplasms 1Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, T-Cell 1Lymphoma, Large-Cell, Immunoblastic 1Immunoblastic Lymphadenopathy 1HIV Infections 1Glioblastoma 1Enteropathy-Associated T-Cell Lymphoma 1Brain Neoplasms 1Astrocytoma 1

Interventions

Gemcitabine 3Cyclophosphamide 3romidepsin 2pembrolizumab 2duvelisib 2Vincristine 2Prednisone 2N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 2Biopsy 2Azacitidine 2tazemetostat 1spartalizumab 1somatostatin, cyclic hexapeptide(Phe-Phe-Trp-Lys-Thr-Phe)- 1sodium-iodide symporter 1sintilimab 1ruxolitinib 1ixazomib 1ivarmacitinib 1fludarabine 1etoposide phosphate 1cemiplimab 1cabiralizumab 1belinostat 1X-Rays 1Watchful Waiting 1Tomography, X-Ray Computed 1Specimen Handling 1Salvage Therapy 1Prednisolone 1Photons 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lymphoma, T-Cell, Peripheral × Carmustine × 90 days × Clear all
NCT06692452 2026-04-01

Tazemetostat Plus CHOP in 1L T-cell Lymphoma

Dana-Farber Cancer Institute

Phase 2 Withdrawn
Lymphoid

Immunoblastic Lymphadenopathy, Lymphoma, Lymphoma, T-Cell, Peripheral, Enteropathy-Associated T-Cell Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡